Pfizer Acquires Metsera in $10B Obesity Drug Deal After Bidding War
TL;DR Summary
Novo Nordisk has abandoned its bid for Metsera after Pfizer secured a $10 billion deal to acquire the U.S. weight-loss drug developer, ending a competitive bidding war.
- Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal Seeking Alpha
- Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits CNBC
- Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk Yahoo Finance
- Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer Bloomberg.com
- Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal The New York Times
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
48%
52 → 27 words
Want the full story? Read the original article
Read on Seeking Alpha